Juvenile Arthritis

January 11, 2022

Plasma samples, collected from 21 patients with systemic juvenile idiopathic arthritis (sJIA), indicate 11 proteins that may help identify patients with active and inactive sJIA.

December 16, 2021

Cannabidiol (CBD) may be used separately or in conjunction with standard treatment to reduce symptoms of juvenile idiopathic arthritis.

December 13, 2021

“Preliminary evidence has suggested that an exercise training could be effective in improving physical function and quality of life in juvenile dermatomyositis, without exacerbating the disease,” investigators stated.

November 11, 2021

Hermine Brunner, MD, MSc, MBA, discusses secukinumab treatment in patients with enthesitis-related arthritis and juvenile psoriatic arthritis.

October 13, 2021

“Considering medical appointments, laboratory tests, medications, and indirect costs, juvenile idiopathic arthritis generates elevated costs, which results in a high economic impact for the family,” investigators stated.

October 05, 2021

Few data exist for the use of golimumab in patients whose uveitis does not respond to adalimumab, a first-line biologic choice in refractory juvenile idiopathic arthritis-associated uveitis.

September 30, 2021

While telemedicine is a valuable tool to provide access to care for families seeking care within a small subspecialty with a limited supply of providers, there was a significantly lower amount of new pediatric patient visits in the beginning of the COVID-19 pandemic.

September 22, 2021

As genetics only play a small role in the risk of developing juvenile idiopathic arthritis, environmental factors, such as infections and antibiotic usage, are believed to be the main cause of the disease.

September 09, 2021

Disease activity, safety, and the occurrence of adverse events were similar in patients with juvenile idiopathic arthritis receiving either etanercept or the biosimilars Benepali and Erelzi.

August 27, 2021

“Juvenile idiopathic arthritis constitutes a significant cause of disability and quality of life impairment in pediatric and adult patients,” investigators stated. “Recent advances in JIA treatment addressing more specific targets have led to better short and long-term disease outcomes."